Servier SAS

Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas PARIS, March 09, 2026 (GLOBE NEWSWIRE) -- kyron.bio , a biotechnology company pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier , an international pharmaceutical group governed by a Foundation. Under the terms of the agreement, kyron.bio will use its technology to glycoengineer an antibody selected by Servier, who will fund the associated research activities. Servier will have the option to further explore antibody engineering and development opportunities based on the outcomes. Financial details are not disclosed. kyron.bio’s proprietary glycoengineering platform can enhance therapeutic performance of antibodies by enabling precise control of the glycan structures to improve efficacy, safety, and scalability. In this partnership kyron.bio will seek to demonstrate clear glycan control on the Servier antibody of interest for a specific pre-determined N-glycoform. To date, engineering of glycans have been under-exploited, due to technical challenges, limiting the use of glycan engineering in drug design. kyron.bio is changing that. The company has developed a scalable, proprietary method to achieve comprehensive control over glycosylation, unlocking the possibility to use precision glycosylation in next generation drug design. Dr. Emilia McLaughlin, founder and Chief Executive Officer of kyron.bio, said, “We are delighted that Servier has chosen to explore the potential of our glycoengineering platform. Servier has deep expertise in therapeutic development and combined with our precision glycosylation technology, this partnership provides a powerful opportunity to unlock new levels of antibody performance and deliver better outcomes for patients. “Precision glycosylation represents a transformative approach in biologics development. By engineering defined glycan pro therapeutic antibodies can be optimized for improved immune engagement, pharmacokinetics, and reduced variability.” In 2024, kyron.bio was the winner of the Servier Golden Ticket award which has provided invaluable support and mentorship through the company’s early translational phase and has developed a foundation for understanding the potential of kyron.bio’s technology. Dr. Emmanuel Nony, Director of External Innovation Europe at Servier, said, “Meeting kyron.bio as a winner of Servier’s Golden Ticket award has enabled our scientists to develop an understanding of the kyron.bio glycan engineering technology and its exciting possibilities in antibody drug design. This collaboration is opening new frontiers for antibody derivatives as well. Together, we are exploring innovative pathways to optimize drug design and production, with a shared commitment to bringing safer and more effective therapies to patients.” kyron.bio’s strategy is to form strategic drug design partnerships with pharmaceutical and biotech companies working on next-generation antibody therapeutics, alongside in house therapeutic development programs. A successful company creation from the French Entrepreneur First Scheme, in 2025 kyron.bio raised €5.5m in a seed round from an experienced syndicate of venture investors including HCVC, Verve Ventures, Entrepreneurs First and Saras Capital, as well as private angel investors and the European Innovation Council. It has established an R&D base at the biotech hub Paris Biotech Santé in the Cochin Hospital. Media images can be found here . About kyron.bio kyron.bio is pioneering precision control of glycosylation in antibody therapeutics to enhance functionality and efficacy. Leveraging both proprietary cell-based systems and structure-guided design, the company unlocks the untapped potential of N-glycans in drug development to address a spectrum of therapeutic indications including oncology, and autoimmune diseases. The company was founded in 2022, to commercialise technology developed by kyron.bio’s founder and CEO Emilia McLaughlin as part of the French Entrepreneur First Program. kyron.bio’s strategy is to form strategic drug design partnerships with pharmaceutical companies working on next-generation antibody therapeutics, to apply its patent-protected glycoengineering technology to improve antibody performance, whilst also building an in-house therapeutics portfolio. Based at Paris Biotech Santé in the Cochin Hospital, Kyron.bio investors include Entrepreneur First, HCVC, Verve Ventures, Entrepreneurs First, Saras Capital, and private angel investors. In addition, the company has received grants from the European Innovation Council and Banque Publique d’investissement France. It was the 2024 recipient of a prestigious Servier Golden Ticket award. Learn more at: Follow us on social media: LinkedIn For further information: At the company - Dr. Emilia McLaughlin, Chief Executive Officer of kyron.bio hello@kyron.bio Media enquiries - Charles Consultants Sue Charles sue@charles-consultants.com +44 7968 726585

France-based kyron.bio, a seed-stage biotechnology company specializing in precision glycosylation of antibody therapeutics, and compatriot biopharma Servier entered a strategic partnership under which kyron.bio will apply its glycoengineering platform to an antibody selected by Servier. Servier will fund the associated research activities and retains an option to further explore antibody engineering and development opportunities based on outcomes. The specific antibody, its molecular target, and the intended disease indication were not disclosed. Under the agreement, kyron.bio will seek to demonstrate precise glycan control on the Servier antibody for a specific, pre-determined N-glycoform. The deal is structured as a funded technology evaluation with an option for expanded collaboration rather than a full co-development or co-commercialization arrangement, with Servier retaining the right to deepen the partnership contingent on proof-of-concept results. Deal context kyron.bio’s glycobiology platform addresses a technical challenge in biologics development: achieving comprehensive, scalable control over the glycan structures attached to antibodies. Glycosylation — the addition of sugar molecules to proteins — can affect antibody effector functions including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. By engineering defined glycan profiles, therapeutic antibodies can potentially be optimized for improved immune engagement and pharmacokinetics. The company uses proprietary cell-based systems and structure-guided design to modify N-glycan structures, a process it describes as precision glycosylation. kyron.bio was founded in 2022 to commercialize technology developed by CEO Emilia McLaughlin as part of the French Entrepreneur First Program. In 2025, the company raised EUR 5.5 million in a seed round from investors including HCVC, Verve Ventures, Entrepreneurs First, Saras Capital, and the European Innovation Council. The kyron.bio Servier partnership originated from kyron.bio winning Servier’s 2024 Golden Ticket award through the Spartners by Servier & BioLabs accelerator at Servier’s Paris-Saclay R&D Institute. That program provided one year of hosting, access to Servier’s laboratories, and mentorship. There were no prior commercial arrangements between the two companies before this partnership. For Servier, which generates approximately EUR 4.7 billion in annual revenue and reinvests 25% into R&D across oncology, cardiovascular, immuno-inflammatory, neuroscience, and diabetes, the deal represents a low-risk evaluation of a platform technology for next-generation antibody therapeutics without disclosed financial commitment beyond research funding. The glycoengineering antibodies space has a limited but notable deal history. The most commercially validated transaction remains Roche’s 2005 acquisition of GlycArt Biotechnology for approximately CHF 235 million. GlycArt’s GlycoMAb technology underpinned the development of obinutuzumab (Gazyva), an afucosylated anti-CD20 antibody with enhanced ADCC, now approved for chronic lymphocytic leukemia and non-Hodgkin lymphoma. In the adjacent Fc engineering space, Xencor has structured multiple platform licensing deals, including a 2016 agreement with Novartis for its XmAb bispecific Fc technology valued at approximately USD 150 million in potential milestones, and a 2022 collaboration with Janssen on bispecific antibodies. Xencor’s platform uses protein engineering rather than glycan modification, making it mechanistically adjacent but distinct from kyron.bio’s approach. Other companies with antibody therapeutics glycosylation capabilities include ProBioGen (GlymaxX technology) and Kyowa Kirin (Potelligent platform for afucosylated antibodies), though specific recent licensing deal terms for glycoengineering platforms are limited in the public domain. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion. SURESNES, France and BRISBANE, Calif., March 6, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026. Continue Reading View PDF This acquisition will reinforce Servier's position in oncology targeted therapies in line with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs. It strengthens Servier's portfolio and expands its oncology pipeline with programs ranging from early stage to phase 3. The combination of Day One's scientific expertise with Servier's established global capabilities advances a shared commitment to delivering innovative solutions for patients worldwide. "This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier's position in rare oncology," said Olivier Laureau, President of Servier. "It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer." "Servier's successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One's mission to bring medicines to patients of all ages with life threatening diseases" said Jeremy Bender, Ph.D., chief executive officer of Day One. "Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low–grade glioma. Importantly, Servier's dedication to the rare disease community preserves the patient–first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve." Contacts Servier Group Laura Visserias [email protected] Day One Biopharmaceuticals Media [email protected] PDF - Logo - 21% more press release views with Request a Demo